Zhonghua Fu

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study

Yuelu Guo, Lixia Ma, Fan Yang, Zhonghua Fu et autres

Background: Plasma cell leukemia (PCL) is a rare and aggressive hematological malignancy. The long-term prognosis of relapsed/refractory plasma cell leukemia (R/R PCL) remains poor, and few treatment options are available for patients with triple-refractory disease. Chimeric antigen receptor (CAR)-T cell therapy targeting …

cn (code pays fourni par la source)

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang et autres

Background Central nervous system lymphoma (CNSL) is a rare but aggressive subtype of lymphoma that presents significant therapeutic challenges. The prognosis for patients with CNSL varies significantly based on several genetic factors, including TP53 mutations, which are among the most critical determinants …

cn (code pays fourni par la source)

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: single-arm, open-label, phase I study

Kai Hu, Fan Yang, Rui Liu, Zhonghua Fu et autres

cn (code pays fourni par la source)